{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:47Z","timestamp":1791874727631,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005343","name":"Fundaci\u00f3n IMSS","doi-asserted-by":"publisher","award":["R-2022-3601-175"],"award-info":[{"award-number":["R-2022-3601-175"]}],"id":[{"id":"10.13039\/501100005343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005343","name":"Fundaci\u00f3n IMSS","doi-asserted-by":"publisher","award":["R-2024-3601-239"],"award-info":[{"award-number":["R-2024-3601-239"]}],"id":[{"id":"10.13039\/501100005343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005343","name":"Fundaci\u00f3n IMSS","doi-asserted-by":"publisher","award":["R-2019-785-052"],"award-info":[{"award-number":["R-2019-785-052"]}],"id":[{"id":"10.13039\/501100005343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-02025-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:39:51Z","timestamp":1747643991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors"],"prefix":"10.1186","volume":"13","author":[{"given":"Florencia","family":"Martinez-Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Andonegui-Elguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Sosa-Eroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Gomez-Apo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurea","family":"Escobar-Espa\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gonzalez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gaytan-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alam","family":"Palma-Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Torres-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Moscona-Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Hinojosa-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Hernandez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roci\u00f3 A.","family":"Chavez-Santoscoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Guinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Y.","family":"Guinto-Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blas E.","family":"Lopez-Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick U.","family":"Zepeda-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick M.","family":"Estrada-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Correa-Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A.","family":"Gonzalez-Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Asenscio-Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Garcia-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cantu-Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio L.","family":"Arreola-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Taniguchi-Ponciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Marrero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"6","key":"2025_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.MCT-15-0891","volume":"15","author":"M Chanal","year":"2016","unstructured":"Chanal M, Chevallier P, Raverot V, Fonteneau G, Lucia K, Monteserin Garcia JL et al (2016) Differential effects of PI3K and dual PI3K\/mTOR Inhibition in rat Prolactin-Secreting pituitary tumors. Mol Cancer Ther 15(6):1261\u20131270. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0891","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2025_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Reviews Clin Oncol 15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Reviews Clin Oncol"},{"issue":"13","key":"2025_CR3","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.3390\/ijms241310952","volume":"24","author":"A Derwich","year":"2023","unstructured":"Derwich A, Sykutera M, Bromi\u0144ska B, Rubi\u015b B, Rucha\u0142a M, Sawicka-Gutaj N (2023) The role of activation of PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways in aggressive pituitary Adenomas\u2014New potential therapeutic Approach\u2014A systematic review. Int J Mol Sci 24(13):10952. https:\/\/doi.org\/10.3390\/ijms241310952","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1677\/jme.0.0330155","volume":"33","author":"M Fernandez","year":"2004","unstructured":"Fernandez M, Sanchez-Franco F, Palacios N, Sanchez I, Fernandez C, Cacicedo L (2004) IGF-I inhibits apoptosis through the activation of the phosphatidylinositol 3-kinase\/Akt pathway in pituitary cells. J Mol Endocrinol 33(1):155\u2013163. https:\/\/doi.org\/10.1677\/jme.0.0330155","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2025_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00018-005-5433-4","volume":"63","author":"S Gerlo","year":"2006","unstructured":"Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R (2006) Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells. Cell Mol Life Sci 63(1):92. https:\/\/doi.org\/10.1007\/s00018-005-5433-4","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2025_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13046-022-02245-0","volume":"41","author":"J Guo","year":"2022","unstructured":"Guo J, Li C, Fang Q, Liu Y, Wang D, Chen Y et al (2022) The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1. J Experimental Clin Cancer Res 41(1):26. https:\/\/doi.org\/10.1186\/s13046-022-02245-0","journal-title":"J Experimental Clin Cancer Res"},{"issue":"12","key":"2025_CR7","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/carcin\/bgaa096","volume":"41","author":"CN Haines","year":"2020","unstructured":"Haines CN, Klingensmith HD, Komara M, Burd CJ (2020) GREB1 regulates PI3K\/Akt signaling to control hormone-sensitive breast cancer proliferation. Carcinogenesis 41(12):1660\u20131670. https:\/\/doi.org\/10.1093\/carcin\/bgaa096","journal-title":"Carcinogenesis"},{"issue":"1","key":"2025_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/endo.143.1.8586","volume":"143","author":"J Hayakawa","year":"2002","unstructured":"Hayakawa J, Ohmichi M, Tasaka K, Kanda Y, Adachi K, Nishio Y et al (2002) Regulation of the PRL promoter by Akt through cAMP response element binding protein. Endocrinology 143(1):13\u201322","journal-title":"Endocrinology"},{"issue":"1","key":"2025_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Therapy 6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"2025_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD (2020) The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20(2):74\u201388. https:\/\/doi.org\/10.1038\/s41568-019-0216-7","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2025_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","volume":"21","author":"AJ Hoy","year":"2021","unstructured":"Hoy AJ, Nagarajan SR, Butler LM (2021) Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer 21(12):753\u2013766. https:\/\/doi.org\/10.1038\/s41568-021-00388-4","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2025_CR12","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41467-020-15075-5","volume":"11","author":"J-I Jun","year":"2020","unstructured":"Jun J-I, Lau LF (2020) CCN1 is an Opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling. Nat Commun 11(1):1242. https:\/\/doi.org\/10.1038\/s41467-020-15075-5","journal-title":"Nat Commun"},{"issue":"1","key":"2025_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G (2020) Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122(1):4\u201322. https:\/\/doi.org\/10.1038\/s41416-019-0650-z","journal-title":"Br J Cancer"},{"issue":"14","key":"2025_CR14","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1158\/1078-0432.CCR-15-0288","volume":"21","author":"M Lee","year":"2015","unstructured":"Lee M, Wiedemann T, Gross C, Leinh\u00e4user I, Roncaroli F, Braren R et al (2015) Targeting PI3K\/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin Cancer Res 21(14):3204\u20133215. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0288","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1159\/000504000","volume":"110","author":"S Lin","year":"2020","unstructured":"Lin S, Zhang A, Zhang X, Wu ZB (2020) Treatment of pituitary and other tumours with Cabergoline: new mechanisms and potential broader applications. Neuroendocrinology 110(6):477\u2013488. https:\/\/doi.org\/10.1159\/000504000","journal-title":"Neuroendocrinology"},{"issue":"9","key":"2025_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z et al (2020) PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 11(9):797. https:\/\/doi.org\/10.1038\/s41419-020-02998-6","journal-title":"Cell Death Dis"},{"issue":"4","key":"2025_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K (2020) Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37(4):471\u2013484. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.007","journal-title":"Cancer Cell"},{"issue":"10","key":"2025_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-Tumor endocrinopathies. N Engl J Med 382(10):937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"issue":"5","key":"2025_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: A review. JAMA 317(5):516. https:\/\/doi.org\/10.1001\/jama.2016.19699","journal-title":"JAMA"},{"issue":"4","key":"2025_CR20","doi-asserted-by":"publisher","first-page":"R331","DOI":"10.1530\/ERC-14-0188","volume":"21","author":"E Monsalves","year":"2014","unstructured":"Monsalves E, Juraschka K, Tateno T, Agnihotri S, Asa SL, Ezzat S et al (2014) The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocrine-related Cancer 21(4):R331\u2013R344. https:\/\/doi.org\/10.1530\/ERC-14-0188","journal-title":"Endocrine-related Cancer"},{"issue":"1","key":"2025_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000497205","volume":"109","author":"NC Olarescu","year":"2019","unstructured":"Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G et al (2019) Aggressive and malignant prolactinomas. Neuroendocrinology 109(1):57\u201369. https:\/\/doi.org\/10.1159\/000497205","journal-title":"Neuroendocrinology"},{"issue":"Supplement4","key":"2025_CR22","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C et al (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neurooncology 25(Supplement4):iv1\u2013iv99. https:\/\/doi.org\/10.1093\/neuonc\/noad149","journal-title":"Neurooncology"},{"key":"2025_CR23","doi-asserted-by":"publisher","first-page":"e46012","DOI":"10.7554\/eLife.46012","volume":"8","author":"M-H Park","year":"2019","unstructured":"Park M-H, Kim AK, Manandhar S, Oh S-Y, Jang G-H, Kang L et al (2019) CCN1 interlinks integrin and Hippo pathway to autoregulate tip cell activity. eLife 8:e46012. https:\/\/doi.org\/10.7554\/eLife.46012","journal-title":"eLife"},{"issue":"12","key":"2025_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting adenomas: a pituitary society international consensus statement. Nat Reviews Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Reviews Endocrinol"},{"issue":"4","key":"2025_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.molmed.2013.02.001","volume":"19","author":"T Rauen","year":"2013","unstructured":"Rauen T, Hedrich CM, Tenbrock K, Tsokos GC (2013) cAMP responsive element modulator: A critical regulator of cytokine production. Trends Mol Med 19(4):262\u2013269. https:\/\/doi.org\/10.1016\/j.molmed.2013.02.001","journal-title":"Trends Mol Med"},{"issue":"4","key":"2025_CR26","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L et al (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative Follow-Up. J Clin Endocrinol Metabolism 95(4):1708\u20131716. https:\/\/doi.org\/10.1210\/jc.2009-1191","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"12","key":"2025_CR27","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1210\/en.2006-0325","volume":"147","author":"D Romano","year":"2006","unstructured":"Romano D, Pertuit M, Rasolonjanahary R, Barnier J-V, Magalon K, Enjalbert et al (2006) Regulation of the RAP1\/RAF-1\/Extracellularly regulated Kinase-1\/2 cascade and prolactin release by the phosphoinositide 3-Kinase\/AKT pathway in pituitary cells. Endocrinology 147(12):6036\u20136045. https:\/\/doi.org\/10.1210\/en.2006-0325","journal-title":"Endocrinology"},{"key":"2025_CR28","doi-asserted-by":"publisher","unstructured":"Roof AK, Jirawatnotai S, Trudeau T, Kuzyk C, Wierman ME, Kiyokawa H, Gutierrez-Hartmann A (2018) The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Endocrinology. 1;159(6):2421\u20132434. https:\/\/doi.org\/10.1210\/en.2017-03135","DOI":"10.1210\/en.2017-03135"},{"issue":"2","key":"2025_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-012-9682-3","volume":"42","author":"H Rubinfeld","year":"2012","unstructured":"Rubinfeld H, Shimon I (2012) PI3K\/Akt\/mTOR and Raf\/MEK\/ERK signaling pathways perturbations in non-functioning pituitary adenomas. Endocrine 42(2):285\u2013291. https:\/\/doi.org\/10.1007\/s12020-012-9682-3","journal-title":"Endocrine"},{"issue":"8","key":"2025_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/emmm.201101131","volume":"4","author":"NA Saunders","year":"2012","unstructured":"Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G et al (2012) Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 4(8):675\u2013684. https:\/\/doi.org\/10.1002\/emmm.201101131","journal-title":"EMBO Mol Med"},{"key":"2025_CR31","doi-asserted-by":"publisher","first-page":"111264","DOI":"10.1016\/j.biopha.2021.111264","volume":"137","author":"M Shao","year":"2021","unstructured":"Shao M, Lu L, Wang Q, Ma L, Tian X, Li C et al (2021) The multi-faceted role of retinoid X receptor in cardiovascular diseases. Biomed Pharmacother 137:111264. https:\/\/doi.org\/10.1016\/j.biopha.2021.111264","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"2025_CR32","doi-asserted-by":"publisher","first-page":"eabe2470","DOI":"10.1126\/sciadv.abe2470","volume":"7","author":"EM Shin","year":"2021","unstructured":"Shin EM, Huynh VT, Neja SA, Liu CY, Raju A, Tan K et al (2021) GREB1: an evolutionarily conserved protein with a glycosyltransferase domain links ER\u03b1 glycosylation and stability to cancer. Sci Adv 7(12):eabe2470. https:\/\/doi.org\/10.1126\/sciadv.abe2470","journal-title":"Sci Adv"},{"issue":"22","key":"2025_CR33","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.3390\/cancers13225796","volume":"13","author":"J Szymczyk","year":"2021","unstructured":"Szymczyk J, Sluzalska K, Materla I, Opalinski L, Otlewski J, Zakrzewska M (2021) FGF\/FGFR-Dependent molecular mechanisms underlying Anti-Cancer drug resistance. Cancers 13(22):5796. https:\/\/doi.org\/10.3390\/cancers13225796","journal-title":"Cancers"},{"issue":"5","key":"2025_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1055\/s-0039-1679636","volume":"10","author":"C Tang","year":"2019","unstructured":"Tang C, Sun R, Wen G, Zhong C, Yang J, Zhu J et al (2019) Bromocriptine and Cabergoline induce cell death in prolactinoma cells via the ERK\/EGR1 and AKT\/mTOR pathway respectively. Cell Death Dis 10(5):335. https:\/\/doi.org\/10.1055\/s-0039-1679636","journal-title":"Cell Death Dis"},{"issue":"1","key":"2025_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40478-024-01796-x","volume":"12","author":"K Taniguchi-Ponciano","year":"2024","unstructured":"Taniguchi-Ponciano K, Hinojosa-Alvarez S, Hernandez-Perez J, Chavez-Santoscoy RA, Remba-Shapiro I, Guinto G et al (2024) Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways. Acta Neuropathol Commun 12(1):142. https:\/\/doi.org\/10.1186\/s40478-024-01796-x","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"2025_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M et al (2020) FGF\/FGFR signaling in health and disease. Signal Transduct Target Therapy 5(1):181. https:\/\/doi.org\/10.1038\/s41392-020-00222-7","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"2025_CR37","doi-asserted-by":"publisher","first-page":"100934","DOI":"10.1016\/j.xcrm.2023.100934","volume":"4","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Yao B, Long X, Chen Z, He M, Wu Y et al (2023) Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET. Cell Rep Med 4(2):100934. https:\/\/doi.org\/10.1016\/j.xcrm.2023.100934","journal-title":"Cell Rep Med"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02025-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02025-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02025-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:39:52Z","timestamp":1747643992000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02025-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2025"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02025-9","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Comisi\u00f3n Nacional de \u00c9tica e Investigaci\u00f3n Cient\u00edfica del Instituto Mexicano del Seguro Social (approval: R-2022-3601-175, R-2022-3601-164 and R-2024-3601-239) and it has been carried out in accordance with the principles of the Helsinki declaration. All participating patients signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}